<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424034</url>
  </required_header>
  <id_info>
    <org_study_id>AMB107623</org_study_id>
    <nct_id>NCT00424034</nct_id>
  </id_info>
  <brief_title>A Study of GSK1325760A in Healthy Japanese Subjects</brief_title>
  <official_title>Phase I Study of Ambrisentan - Single Dose Study in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerability, pharmacokinetics and the effect of food on&#xD;
      pharmacokinetics after single oral administrations of GSK1325760A&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase1 study of GSK1325760A&#xD;
&#xD;
      - A double blind, single center, randomised, placebo-controlled, partially crossover, single&#xD;
      dose study to investigate the safety, tolerability, pharmacokinetics and to assess the effect&#xD;
      of food on pharmacokinetics of ascending oral doses of GSK1325760A in healthy Japanese male&#xD;
      subject -&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events Change in Clinical laboratory test Vital sign 12-lead ECG Plasma concentration Urine concentration</measure>
    <time_frame>on 5 or 6 days after dosing</time_frame>
  </primary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1325760A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  They are considered as healthy by the investigator at screening. Healthy subjects are&#xD;
             defined as individuals who are free from clinically significant illness or disease as&#xD;
             determined by their medical history, physical examination, clinical laboratory tests,&#xD;
             vital sign, 12-lead ECG, immunology tests and urinary drug screening tests.&#xD;
&#xD;
          -  They are Japanese males.&#xD;
&#xD;
          -  Aged 20 to 64 years, inclusive.&#xD;
&#xD;
          -  They have a body mass index (weight/height2) at screening in the range of 18.5 and&#xD;
             &lt;25.0 kg/m2 inclusive. Standard weight is in the range of 55-85 kg inclusive.&#xD;
&#xD;
          -  Blood pressure and pulse rate at screening within the normal range (systolic 90-140&#xD;
             mmHg, diastolic 40-90 mmHg, pulse rate 40-90bpm).&#xD;
&#xD;
          -  They have the following clinical laboratory test&#xD;
&#xD;
          -  Biochemistry (AST(GOT), ALT(GPT), ALP, LDH and gamma-GTP : within normal range at&#xD;
             screening.&#xD;
&#xD;
          -  Haematology (RBC, Hb and Ht) below upper limit normal range at screening.&#xD;
&#xD;
          -  Normal ECG at screening (QTc value of &lt;440msec).&#xD;
&#xD;
          -  They give their consent to be able to abstain from sexual intercourse or use condom&#xD;
             for contraception from at screening until post-study screen.&#xD;
&#xD;
          -  They are capable of giving written informed consent, which includes compliance with&#xD;
             the requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  They are non-smokers (at least 6 months).&#xD;
&#xD;
          -  They are able to attend all visits and complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any clinically relevant abnormality on medical examination, vital&#xD;
             sign, clinical laboratory test or medical history at screening in the medical opinion&#xD;
             of the investigator or the subject has a medical history that is not considered as&#xD;
             eligible for inclusion in this study by the investigator.&#xD;
&#xD;
          -  The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen&#xD;
             allergy without current symptoms.&#xD;
&#xD;
          -  The subject has participated in a clinical study or post-marketing study with an&#xD;
             investigational or a non-investigational product or device during the previous 4&#xD;
             months of the first dosing.&#xD;
&#xD;
          -  The subject is concurrently participating in another clinical study or post-marketing&#xD;
             study in which the subject is or will be exposed to an investigational or a&#xD;
             non-investigational product or device.&#xD;
&#xD;
          -  The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1&#xD;
             antibody.&#xD;
&#xD;
          -  The subject is positive for urine drugs of abuse test.&#xD;
&#xD;
          -  The subject has donated a unit of blood (&gt;400mL) within the previous 4 months or&#xD;
             (&gt;200mL) within the previous 1 month of screening.&#xD;
&#xD;
          -  The subject is currently taking regular (or a course of) medication (including&#xD;
             prescribed drug, over-the-counter medication and herbal preparations). Medication nor&#xD;
             permitted during the study must be discontinued 14 days prior to dosing.&#xD;
&#xD;
          -  The subject has a history or current conditions of drug abuse or alcoholism according&#xD;
             to ICD10.&#xD;
&#xD;
          -  The subject has a history of regular alcohol consumption exceeding 7 drinks/week (1&#xD;
             drink = 350mL of beer) within 6 months of the first dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>effect of food on pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

